Significance of Endocan Expression in Various Types of Epithelial Ovarian Tumors
Open Access
- 8 March 2022
- journal article
- research article
- Published by Farname, Inc. in Iranian Journal of Pathology
- Vol. 17 (2) , 202-209
Abstract
Background & Objective: Ovarian cancer is associated with the highest mortality rate among gynecologic malignancies. Despite new therapeutic strategies, ovarian cancer still has a high risk of metastasis and mortality. Endocan is a newly identified endothelial cell activation marker, which is responsible for angiogenesis, tumor invasion, and aggressive behavior of tumors. The aim of this study was to assess Endocan expression in different types of ovarian tumors and to identify its relationship with clinicopathologic characteristics of ovarian tumors.Methods: This cross-sectional study was conducted on 183 tissue samples, including benign, borderline, and malignant ovarian tumors collected from the University Kebangsaan Malaysia Medical Center archive of Pathology during 2005-2015. Mouse monoclonal anti-human Endocan/ESM-1 Clone MEP08 was used at a dilution of 1:400 for immunohistochemical (IHC) staining. All the information was collected by a checklist, and the association between clinicopathological features and high or low levels of Endocan -MVD was evaluated using Pearson chi-square, Fischer's exact, or Monte Carlo tests.Results: The prevalence of Endocan positivity was significantly higher in malignant compared to borderline and benign ovarian tumors (P<0.001). There was also a significant association between type of tumor and Endocan status in malignant ovarian tumors (P=0.02), indicating that Endocan positivity was more likely in serous malignant ovarian tumors compared to other ovarian tumor types. However, the tumor stage was not significantly associated with Endocan status (P=0.31).Conclusion: This study showed that Endocan positivity may show the highest prevalence among malignant tumors suggesting that high Endocan expression would be negatively associated with ovarian tumor behavior.Keywords
This publication has 47 references indexed in Scilit:
- Sortilin as a Regulator of Lipoprotein MetabolismCurrent Atherosclerosis Reports, 2012
- Sortilin: a receptor to regulate neuronal viability and functionTrends in Neurosciences, 2012
- Antibody therapy of cancerNature Reviews Cancer, 2012
- Pro-nerve Growth Factor Induces Autocrine Stimulation of Breast Cancer Cell Invasion through Tropomyosin-related Kinase A (TrkA) and Sortilin ProteinJournal of Biological Chemistry, 2012
- Neurotensin-induced Erk1/2 phosphorylation and growth of human colonic cancer cells are independent from growth factors receptors activationBiochemical and Biophysical Research Communications, 2011
- Fine-Tuning Roles of Endogenous Brain-Derived Neurotrophic Factor, TrkB and Sortilin in Colorectal Cancer Cell SurvivalPLOS ONE, 2011
- Multiplexed Methylation Profiles of Tumor Suppressor Genes in Bladder CancerThe Journal of Molecular Diagnostics, 2011
- NRH2 is a trafficking switch to regulate sortilin localization and permit proneurotrophin‐induced cell deathThe EMBO Journal, 2009
- Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell linesInternational Journal of Cancer, 2001
- Molecular Identification of a Novel Candidate Sorting Receptor Purified from Human Brain by Receptor-associated Protein Affinity ChromatographyJournal of Biological Chemistry, 1997